Clinical Trials Logo

Clinical Trial Summary

Chronic pain patients who experience breakthrough pain in the background of controlled persistent pain with opioids will be followed for 3 months in order to assess the safety and titration trends in the clinical practice setting of a novel fentanyl sublingual spray (Subsys™) for the treatment of breakthrough pain.


Clinical Trial Description

Approximately 100 subjects across 10 centers throughout the United States will be enrolled into the study. Subjects who are currently taking Actiq® for their breakthrough pain and will be discontinued due to lack of efficacy, poor tolerability, patient or prescriber dissatisfaction and meet all other study inclusion criteria and none of the exclusion criteria will be candidates to receive a sublingual fentanyl spray (Subsys™). The total duration of the study for each subject will be no more than 4 months. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01901718
Study type Observational
Source International Clinical Research Institute
Contact
Status Terminated
Phase N/A
Start date April 2013
Completion date January 2014

See also
  Status Clinical Trial Phase
Completed NCT00994760 - Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years N/A
Completed NCT01842893 - Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer Phase 3
Completed NCT02886286 - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain Phase 4
Completed NCT02869321 - Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Phase 4
Completed NCT02840500 - Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units N/A
Completed NCT02437929 - Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment N/A
Completed NCT00236145 - Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain Phase 3
Completed NCT02836379 - Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent N/A
Active, not recruiting NCT02278601 - Comparison of Regimens MPIB, CIPCEA, PCEA Phase 3
Terminated NCT00842829 - Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients Phase 4
Recruiting NCT05200806 - A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy Phase 4
Withdrawn NCT03809455 - Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients Phase 2
Completed NCT03435120 - Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Completed NCT02050503 - Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis N/A
Terminated NCT00387010 - Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain Phase 3
Withdrawn NCT05053308 - Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement N/A
Recruiting NCT04011150 - Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour Phase 3
Completed NCT00402350 - Staccato Fentanyl Single and Multidose PK Phase 1
Completed NCT00236041 - Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) Phase 2